The first Chinese self-developed breast biopsy & resection technology is approved by CFDA

A big step for Chinese Women Health

There are about 1.67 million women in the world suffering from breast cancer, and 520,000 deaths of breast cancer every year. The incidence rate of breast cancer among Chinese women has increased threefold in the past 5 years, and there are nearly 50,000 deaths of breast cancer in China every year, among which 84% of breast cancer patients was caused by ignoring early detection and treatment.

In order to determine whether the breast abnormality is benign or malignant, it is necessary to perform biopsy on the lesion to make accurate pathological diagnosis, via pathological tissue samples with minimally invasive biopsy and rotary resection system.

Breast biopsy and rotary resection system performs part or all minimal biopsy sampling on target abnormal tissues, puncture guided by ultrasound images, after checking exception with imaging or touching examination for the mammary tissue of patient, XISHAN digital breast biopsy and rotary resection electric control system is a domestic initiative to provide sampling scheme for clinical in a smooth, reliable, intelligent, fast, safe way.

XISHAN breast biopsy and rotary resection system(DK-B-MS) is supposed to change the condition that Chinese hospital replying on importing brands with higher cost, and difficult to popularize early detection and prevention from breast malignant tumor. With good performance and policy support, XISHAN DK-B-MS has large potential to contribute to Chinese Women Health, even global women health in the coming future.

On 13th May, 2020, XISHAN DK-B-MS that self-developed by XISHAN with independent intellectual property rights is approved by the State Food and Drug Administration, with Registration No. 国械注准20203140459. Let's stay tune!